The protective mechanism of Bu-Zhong-Yi-Qi in pelvic organ prolapse is revealed through network pharmacology and molecular docking.

Researchers investigated how Bu-Zhong-Yi-Qi decoction (BZYQD), a traditional Chinese herbal formula, might help women with pelvic organ prolapse (POP), a condition where pelvic organs drop from their normal position. Using advanced computer analysis, scientists identified 504 compounds in the formula, with 13 active ingredients showing particular promise, including benzenepropanoic acid and narirutin. The study found that these herbal compounds interact with 96 specific targets in the body related to POP. The formula appears to work through multiple pathways, particularly by reducing oxidative stress, controlling inflammation, and helping remodel the tissue that supports pelvic organs. The research identified 10 key genes that the formula influences, including those involved in tissue breakdown (MMP2, MMP3, MMP9) and cellular processes. Computer simulations showed that the active compounds bind well to these target proteins, suggesting they could effectively influence the disease process. This study is significant because it uses modern scientific methods to understand how traditional Chinese medicine works at a molecular level. While BZYQD shows promise as a multi-target therapy for pelvic organ prolapse, the researchers emphasize that this is laboratory-based research using computer modeling. Clinical trials with actual patients are still needed to confirm whether the formula is safe and effective for treating POP in real-world settings. If you're considering acupuncture or Chinese herbal medicine for pelvic health concerns, seek care from a licensed acupuncturist or herbalist with experience treating women's health conditions.

This network pharmacology study investigated Bu-Zhong-Yi-Qi decoction's (BZYQD) mechanisms in pelvic organ prolapse (POP) management using liquid chromatography-tandem mass spectrometry, database mining (Swiss Target Prediction, GEO, DisGeNET), and molecular docking simulations. Researchers identified 504 compounds with 13 active ingredients (notably benzenepropanoic acid and narirutin) targeting 96 POP-related genes. Gene Ontology and pathway analyses revealed 28 key targets affecting oxidative stress, inflammatory responses, and extracellular matrix remodeling. High-degree network genes included PTGS2, ESR2, ESR1, MMP3, CASP3, MAPK1, MMP2, MMP9, PPARG, and CTNNB1. Molecular docking demonstrated favorable binding affinities, with benzenepropanoic acid showing lowest binding free energy to MMP2. No sample size or effect sizes reported as this was computational modeling without clinical intervention. Clinical takeaway: BZYQD demonstrates multi-target potential for POP through matrix metalloproteinase modulation and anti-inflammatory mechanisms, supporting its traditional use for prolapse conditions, though clinical trials are required for validation.